Genomic Valley Biotech Ltd Stock Price Today (NSE: GVBL)

Genomic Valley Biotech Ltd

30.20+0.00 (+0.00%)
Market Closed

Fundamental Score

...

Genomic Valley Biotech Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Genomic Valley Biotech Ltd share price today is 30.20, up +0.00% on NSE/BSE as of 16 September 2026. Genomic Valley Biotech Ltd (GVBL) is a Small-cap company in the Biotechnology sector with a market capitalisation of 8.73 (Cr). The 52-week high for GVBL share price is 41.00 and the 52-week low is 20.10. At a P/E ratio of 290.85x, GVBL is currently trading above its industry average P/E of 46.63x. The company has a Return on Equity (ROE) of 0.77% and a debt-to-equity ratio of 0.00.

Genomic Valley Biotech Ltd Share Price Chart — NSE/BSE Historical Performance

No data
High
31.85
Low
26.15
Volume
823.7083333333334
Change
-2.14%

Genomic Valley Biotech Ltd share price chart: -2.14% return over the past month. 52-week high ₹41.00, 52-week low ₹20.10.

Genomic Valley Biotech Ltd — Last 10 Trading Days

DateOpenHighLowCloseVolume
31.7031.7028.8728.87103.00 (Cr)
30.5030.5030.2130.21150.00 (Cr)
31.8531.8530.5031.80380.00 (Cr)
30.4030.4030.4030.400.00 (Cr)
30.4031.4430.4030.40243.00 (Cr)
29.5130.4928.1030.491.07K (Cr)
29.5029.5129.5029.513.12K (Cr)
31.0231.0228.1029.50751.00 (Cr)
31.5031.5029.5529.55789.00 (Cr)
28.5030.4028.5030.40501.00 (Cr)

Genomic Valley Biotech Ltd — Last 12 Months Price History

MonthOpenHighLowCloseChange
28.0031.8527.8528.87+3.11%
29.5031.7526.1527.55-6.61%
26.5435.1125.2530.25+13.98%
24.5026.6722.0526.54+8.33%
26.7529.9523.0424.25-9.35%
28.5029.9420.5828.00-1.75%
21.4129.5020.2028.50+33.12%
25.4929.9020.1025.90+1.61%
30.0030.3521.0124.71-17.63%
30.1038.2027.1530.66+1.86%
32.3534.0027.1530.40-6.03%
41.0041.0032.3132.52-20.68%

Returns & Performance

Poor

Return on Equity (ROE)

0.77%

Profit generated per ₹1 of shareholder equity

Poor

Return on Capital (ROCE)

1.02%

Returns generated on total capital deployed

Excellent

Oper. Profit Margin (5Y Avg)

24.57%

Average operating profit margin over 5 years

Dividend Yield

0.00%

Annual dividend as % of current share price

Genomic Valley Biotech Ltd Valuation Check

Poor

Price to Earnings (P/E)

290.85x

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

46.63x

Average P/E of all peers in this sector

Market-cap Classification
Small-cap
Higher growth potential with higher volatility.

Shareholding Pattern

Excellent

Promoter Holding

46.06%

% shares held by company founders/management

Poor

FII Holding

0.00%

% shares held by foreign institutional investors

Poor

DII Holding

0.00%

% held by domestic mutual funds, LIC, banks

Excellent

Promoter Pledged %

0.00%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Excellent

Profit Growth (Quarterly YoY)

87.50%

Net profit growth vs same quarter last year

Poor

Revenue Growth (Quarterly YoY)

-84.62%

Revenue growth vs same quarter last year

Poor

Revenue Growth (5-Year CAGR)

5.15%

Compounded annual revenue growth over 5 years

Excellent

EPS Growth (5-Year CAGR)

15.48%

Earnings per share growth over 5 years

Excellent

Net Profit Growth (5-Year CAGR)

15.48%

Compounded annual net profit growth over 5 years

Balance Sheet Health

Excellent

Debt to Equity Ratio

0.00x

Total debt ÷ equity. Below 0.5 = financially healthy

Interest Coverage Ratio

N/A

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

3.90 (Cr)

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Genomic Valley Biotech Ltd Fundamental Analysis & Valuation Benchmarking

Educational evaluation of GVBL across key market metrics for learning purposes.

Positive Indicators

7 factors identified

Strong Operating Margins (24.57%)

Observation: Healthy 5-year operating margins indicate pricing power and cost control.

Analysis: OPM >15% suggests operational efficiency and competitive advantages.

Robust Profit Growth (87.50%)

Observation: Strong year-over-year profit expansion demonstrates business momentum.

Analysis: Profit growth >20% indicates effective execution and market opportunity capture.

Excellent EPS Growth (15.48% CAGR)

Observation: Outstanding 5-year earnings per share compound growth.

Analysis: EPS CAGR >15% indicates strong wealth creation potential.

Strong Profit Growth Track Record (15.48% CAGR)

Observation: Consistent 5-year profit compound annual growth rate.

Analysis: Profit CAGR >15% demonstrates scalable business model.

Debt-Free Balance Sheet (D/E: 0.00)

Observation: Low leverage provides financial flexibility and reduced risk.

Analysis: Conservative debt structure offers resilience during economic downturns.

Healthy Liquidity Position (Current Ratio: 5.73)

Observation: Strong short-term liquidity to meet obligations.

Analysis: Current ratio >1.5 indicates good working capital management.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

5 factors identified

Below-Average Return on Equity (0.77%)

Observation: Returns on equity are below industry benchmarks.

Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.

Suboptimal ROCE (1.02%)

Observation: Returns on capital employed are below expectations.

Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.

Premium Valuation Risk (P/E: 290.85x)

Observation: High valuation multiples may limit upside potential.

Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.

Revenue Contraction (-84.62%)

Observation: Sales decline may indicate market challenges or competitive pressures.

Analysis: Negative revenue growth requires analysis of market conditions.

No Dividend Distribution

Observation: Company does not currently pay dividends to shareholders.

Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.

Genomic Valley Biotech Ltd vs Biotechnology Peers

Peer Comparison - Biotechnology

Compare Genomic Valley Biotech Ltd with 4 other companies in the same sector

5 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
36.4/100
30
₹8.73
290.9
Average
0.77%
Poor
1.02%
Poor
0.0
Excellent
15.48%
Excellent
5.15%
Good
0.00%
65.9/100
943
₹53124.39
69.2
Average
22.28%
Excellent
30.37%
Excellent
0.0
Excellent
17.48%
Excellent
14.00%
Good
0.27%
63.4/100
300
₹3353.65
20.2
Average
11.05%
Average
14.44%
Average
0.0
Excellent
2.91%
Average
8.24%
Good
1.63%
9/100
28
₹475.35
-2.92%
Poor
-2.92%
Poor
0.0
Excellent
0.00%
8.1/100
19
₹51.86
-2.00%
Poor
7.29%
Poor
0.7
Good
0.59%
Average
0.00%

Genomic Valley Biotech Ltd PE Ratio History

Historical price-to-earnings ratio for GVBL — last 5 years

YearEPS (₹)Price (₹)P/E Ratio
FY 20251.17₹24.7121.1x
FY 20240.05₹79.951599x

P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.

Genomic Valley Biotech Ltd Quarterly Performance

Latest quarterly metrics for GVBL — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

-84.62%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

87.50%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

5.15%

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

15.48%

Compounded annual net profit growth over 5 years

Genomic Valley Biotech Ltd Technical Indicators

SMA 50, SMA 200, RSI and volume signals for GVBL — calculated from daily price history

45RSI 14
Neutral — RSI 45

Momentum is balanced — neither overbought nor oversold.

SMA 50
30
▲ Price above SMA 50 — Short-term bullish
SMA 200
27
▲ Price above SMA 200 — Long-term uptrend
30-Day Avg Volume
1K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

Genomic Valley Biotech Ltd Financial Statements

Annual income statement, balance sheet and cash flow for Genomic Valley Biotech Ltd (GVBL) — sourced from NSE/BSE filings.

Financial Results & Statements

Latest quarterly, annual and period-wise financial data for Genomic Valley Biotech Ltd

Loading latest quarterly results...

About GVBL (Genomic Valley Biotech Ltd)

Genomic Valley Biotech Ltd is a pioneering force in the Indian biotechnology landscape, specializing in the meticulous cultivation and enhancement of agricultural resources. Throug...h innovative approaches, GVBL focuses on leveraging cutting-edge genomic techniques to improve crop yields, enhance nutritional value, and bolster resilience against environmental stressors. The company's research and development initiatives are dedicated to the identification and propagation of superior plant varieties, employing advanced breeding methodologies and genetic engineering to develop crops with enhanced traits, such as disease resistance, pest tolerance, and improved shelf life. GVBL operates state-of-the-art laboratories and cultivation facilities, where scientists and agricultural experts collaborate to translate groundbreaking research into tangible solutions for the agricultural sector. GVBL's commitment to sustainable agricultural practices is reflected in its emphasis on environmentally friendly cultivation methods. The company actively promotes the use of bio-fertilizers, biopesticides, and water conservation technologies to minimize the environmental impact of its operations. Through precision agriculture techniques and data-driven analysis, GVBL optimizes resource utilization and minimizes waste, ensuring both economic efficiency and ecological responsibility. The company also engages in collaborative projects with farmers and agricultural communities, providing training and support to promote the adoption of sustainable farming practices. By integrating scientific innovation with environmental stewardship, GVBL aims to contribute to a more resilient and sustainable agricultural ecosystem. Beyond its core focus on crop improvement, GVBL is actively involved in developing novel biotechnological solutions for various agricultural challenges. The company's research portfolio includes the development of diagnostic tools for plant diseases, the creation of biostimulants to enhance plant growth, and the exploration of microbial solutions for soil health management. GVBL is dedicated to addressing the evolving needs of the agricultural sector, collaborating with industry partners, research institutions, and government agencies to accelerate the development and deployment of innovative biotechnological solutions. By fostering collaboration and embracing cutting-edge technologies, GVBL is poised to drive advancements in agricultural productivity and contribute to food security in India and beyond.

Company Details

Symbol:GVBL
Industry:Biotechnology
Sector:Biotechnology

Key Leadership

Mr. Yogesh Agrawal
MD, Chairman & CFO
Ms. Anupam Aditya
Company Secretary & Compliance Officer

GVBL Share Price: Frequently Asked Questions

What is the current share price of Genomic Valley Biotech Ltd?

Genomic Valley Biotech Ltd (GVBL) trades at ₹30.20 on NSE and BSE. Market cap ₹8.73 (Cr). Educational data only.

What is the P/E ratio of Genomic Valley Biotech Ltd?

Genomic Valley Biotech Ltd has a P/E of 290.85x vs industry average 46.63x.

What is the Bull Run score for Genomic Valley Biotech Ltd?

Genomic Valley Biotech Ltd has a Bull Run score of 36.4/100 based on 25+ financial parameters.

Does Genomic Valley Biotech Ltd pay dividends?

Genomic Valley Biotech Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.

What is the ROE of Genomic Valley Biotech Ltd?

Genomic Valley Biotech Ltd has ROE of 0.77%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Genomic Valley Biotech Ltd?

Genomic Valley Biotech Ltd has debt-to-equity of 0.00.

Is Genomic Valley Biotech Ltd a good investment?

Bull Run gives Genomic Valley Biotech Ltd a score of 36.4/100. This is not investment advice — consult a SEBI-registered advisor.